(MedPage Today) — There was strong evidence for extending dual antiplatelet therapy (DAPT) beyond the standard 12 months in selected patients with multivessel coronary artery disease (CAD), the DAPT-MVD trial found. These were nonelderly patients…
Source: MedPage Today — Headlines
